A clinical investigation on the characteristics and outcomes of treating chronic lower extremity wounds using the tissuetech autograft system.

The application of tissue engineering technology to wound healing has resulted in the development of a number of "living skin equivalents." These have become a viable option in the treatment of chronic, nonhealing wounds. Such wounds present a major cost burden as well as increased morbidity and mortality. Unique among skin tissue engineering technology is the TissueTech autograft system, as it incorporates an autologous dermal substitute-Hyalograft 3D-and an autologous epidermal replacement, Laserskin autograft. Each includes a matrix of a hyaluronic acid ester to promote cellular migration and graft take.